Odds Ratios Obtained With Unadjusted and Adjusted Logistic Regression Assessing the Relationship of Variables to In-Hospital Death
| Variable . | Unadjusted Regression Model . | Adjusted Regression Model . | ||
|---|---|---|---|---|
| OR (95% CI) . | P Value . | OR (95% CI) . | P Value . | |
| Age (in years) | 1.0 (1.0–1.0) | .04 | 1.01 (.99–1.04) | .3 |
| Male sex | 0.89 (.55–1.4) | .63 | 0.57 (.33–1.00) | .05 |
| Diabetes | 1.3 (.80–2.2) | .29 | … | … |
| Liver disease | 1.5 (.82–2.7) | .19 | … | … |
| Chronic kidney disease | 1.1 (.6–1.8) | .85 | … | … |
| Cancer | 1.7 (1.0–2.7) | .05 | … | … |
| Solid tumor | 0.89 (.47–1.7) | .72 | 0.91 (.40–2.08) | .83 |
| Hematologic cancer | 2.5 (1.4–4.6) | <.01 | 4.48 (2.13–9.41) | <.001 |
| Immunosuppression | 1.4 (.83–2.2) | .23 | … | … |
| ANC <500/µL | 2.4 (1.2–4.9) | .02 | … | … |
| Charlson comorbidity index | 1.1 (1.0–1.2) | .04 | 1.14 (.99–1.30) | .06 |
| Infection source | ||||
| Abdominal | 0.8 (.47–1.3) | .39 | … | … |
| Urinary tract | 0.58 (.3–1.1) | .09 | … | … |
| Central catheter | 0.42 (.13–1.4) | .15 | … | … |
| Respiratory tract | 8.1 (3.9–16.9) | <.001 | 5.35 (2.23–12.79) | <.001 |
| Unidentified | 0.92 (.52–1.7) | .79 | … | … |
| Antibiotic resistant | ||||
| Ceftriaxone | 2.1 (1.2–3.5) | .01 | … | … |
| Cefepime | 3.8 (1.9–7.7) | <.001 | … | … |
| Piperacillin-tazobactam | 2.9 (1.5–5.5) | .00 | … | … |
| Aminoglycoside | 1.9 (.93–3.9) | .08 | … | … |
| Fluoroquinolone | 1.4 (.76–2.4) | .29 | … | … |
| MDR | 1.7 (.94–3.1) | .08 | … | … |
| Delay of ≥4 h to antibiotic treatment | 1.5 (.9–2.4) | .12 | … | … |
| Incorrect 1st antibiotic | 3.8 (1.9–7.7) | <.001 | 5.22 (2.21–12.37) | <.001 |
| ID consultation | 0.83 (.51–1.3) | .44 | … | … |
| Hospital-acquired infection | 2.8 (1.7–4.5) | <.001 | … | … |
| ICU admission | 4.72 (2.86–7.79) | <.001 | 5.06 (2.82–9.07) | <.001 |
| Variable . | Unadjusted Regression Model . | Adjusted Regression Model . | ||
|---|---|---|---|---|
| OR (95% CI) . | P Value . | OR (95% CI) . | P Value . | |
| Age (in years) | 1.0 (1.0–1.0) | .04 | 1.01 (.99–1.04) | .3 |
| Male sex | 0.89 (.55–1.4) | .63 | 0.57 (.33–1.00) | .05 |
| Diabetes | 1.3 (.80–2.2) | .29 | … | … |
| Liver disease | 1.5 (.82–2.7) | .19 | … | … |
| Chronic kidney disease | 1.1 (.6–1.8) | .85 | … | … |
| Cancer | 1.7 (1.0–2.7) | .05 | … | … |
| Solid tumor | 0.89 (.47–1.7) | .72 | 0.91 (.40–2.08) | .83 |
| Hematologic cancer | 2.5 (1.4–4.6) | <.01 | 4.48 (2.13–9.41) | <.001 |
| Immunosuppression | 1.4 (.83–2.2) | .23 | … | … |
| ANC <500/µL | 2.4 (1.2–4.9) | .02 | … | … |
| Charlson comorbidity index | 1.1 (1.0–1.2) | .04 | 1.14 (.99–1.30) | .06 |
| Infection source | ||||
| Abdominal | 0.8 (.47–1.3) | .39 | … | … |
| Urinary tract | 0.58 (.3–1.1) | .09 | … | … |
| Central catheter | 0.42 (.13–1.4) | .15 | … | … |
| Respiratory tract | 8.1 (3.9–16.9) | <.001 | 5.35 (2.23–12.79) | <.001 |
| Unidentified | 0.92 (.52–1.7) | .79 | … | … |
| Antibiotic resistant | ||||
| Ceftriaxone | 2.1 (1.2–3.5) | .01 | … | … |
| Cefepime | 3.8 (1.9–7.7) | <.001 | … | … |
| Piperacillin-tazobactam | 2.9 (1.5–5.5) | .00 | … | … |
| Aminoglycoside | 1.9 (.93–3.9) | .08 | … | … |
| Fluoroquinolone | 1.4 (.76–2.4) | .29 | … | … |
| MDR | 1.7 (.94–3.1) | .08 | … | … |
| Delay of ≥4 h to antibiotic treatment | 1.5 (.9–2.4) | .12 | … | … |
| Incorrect 1st antibiotic | 3.8 (1.9–7.7) | <.001 | 5.22 (2.21–12.37) | <.001 |
| ID consultation | 0.83 (.51–1.3) | .44 | … | … |
| Hospital-acquired infection | 2.8 (1.7–4.5) | <.001 | … | … |
| ICU admission | 4.72 (2.86–7.79) | <.001 | 5.06 (2.82–9.07) | <.001 |
Abbreviations: ANC, absolute neutrophil count; CI, confidence interval; ICU, intensive care unit; ID, infectious diseases; MDR, multidrug resistance; OR, odds ratio.
Odds Ratios Obtained With Unadjusted and Adjusted Logistic Regression Assessing the Relationship of Variables to In-Hospital Death
| Variable . | Unadjusted Regression Model . | Adjusted Regression Model . | ||
|---|---|---|---|---|
| OR (95% CI) . | P Value . | OR (95% CI) . | P Value . | |
| Age (in years) | 1.0 (1.0–1.0) | .04 | 1.01 (.99–1.04) | .3 |
| Male sex | 0.89 (.55–1.4) | .63 | 0.57 (.33–1.00) | .05 |
| Diabetes | 1.3 (.80–2.2) | .29 | … | … |
| Liver disease | 1.5 (.82–2.7) | .19 | … | … |
| Chronic kidney disease | 1.1 (.6–1.8) | .85 | … | … |
| Cancer | 1.7 (1.0–2.7) | .05 | … | … |
| Solid tumor | 0.89 (.47–1.7) | .72 | 0.91 (.40–2.08) | .83 |
| Hematologic cancer | 2.5 (1.4–4.6) | <.01 | 4.48 (2.13–9.41) | <.001 |
| Immunosuppression | 1.4 (.83–2.2) | .23 | … | … |
| ANC <500/µL | 2.4 (1.2–4.9) | .02 | … | … |
| Charlson comorbidity index | 1.1 (1.0–1.2) | .04 | 1.14 (.99–1.30) | .06 |
| Infection source | ||||
| Abdominal | 0.8 (.47–1.3) | .39 | … | … |
| Urinary tract | 0.58 (.3–1.1) | .09 | … | … |
| Central catheter | 0.42 (.13–1.4) | .15 | … | … |
| Respiratory tract | 8.1 (3.9–16.9) | <.001 | 5.35 (2.23–12.79) | <.001 |
| Unidentified | 0.92 (.52–1.7) | .79 | … | … |
| Antibiotic resistant | ||||
| Ceftriaxone | 2.1 (1.2–3.5) | .01 | … | … |
| Cefepime | 3.8 (1.9–7.7) | <.001 | … | … |
| Piperacillin-tazobactam | 2.9 (1.5–5.5) | .00 | … | … |
| Aminoglycoside | 1.9 (.93–3.9) | .08 | … | … |
| Fluoroquinolone | 1.4 (.76–2.4) | .29 | … | … |
| MDR | 1.7 (.94–3.1) | .08 | … | … |
| Delay of ≥4 h to antibiotic treatment | 1.5 (.9–2.4) | .12 | … | … |
| Incorrect 1st antibiotic | 3.8 (1.9–7.7) | <.001 | 5.22 (2.21–12.37) | <.001 |
| ID consultation | 0.83 (.51–1.3) | .44 | … | … |
| Hospital-acquired infection | 2.8 (1.7–4.5) | <.001 | … | … |
| ICU admission | 4.72 (2.86–7.79) | <.001 | 5.06 (2.82–9.07) | <.001 |
| Variable . | Unadjusted Regression Model . | Adjusted Regression Model . | ||
|---|---|---|---|---|
| OR (95% CI) . | P Value . | OR (95% CI) . | P Value . | |
| Age (in years) | 1.0 (1.0–1.0) | .04 | 1.01 (.99–1.04) | .3 |
| Male sex | 0.89 (.55–1.4) | .63 | 0.57 (.33–1.00) | .05 |
| Diabetes | 1.3 (.80–2.2) | .29 | … | … |
| Liver disease | 1.5 (.82–2.7) | .19 | … | … |
| Chronic kidney disease | 1.1 (.6–1.8) | .85 | … | … |
| Cancer | 1.7 (1.0–2.7) | .05 | … | … |
| Solid tumor | 0.89 (.47–1.7) | .72 | 0.91 (.40–2.08) | .83 |
| Hematologic cancer | 2.5 (1.4–4.6) | <.01 | 4.48 (2.13–9.41) | <.001 |
| Immunosuppression | 1.4 (.83–2.2) | .23 | … | … |
| ANC <500/µL | 2.4 (1.2–4.9) | .02 | … | … |
| Charlson comorbidity index | 1.1 (1.0–1.2) | .04 | 1.14 (.99–1.30) | .06 |
| Infection source | ||||
| Abdominal | 0.8 (.47–1.3) | .39 | … | … |
| Urinary tract | 0.58 (.3–1.1) | .09 | … | … |
| Central catheter | 0.42 (.13–1.4) | .15 | … | … |
| Respiratory tract | 8.1 (3.9–16.9) | <.001 | 5.35 (2.23–12.79) | <.001 |
| Unidentified | 0.92 (.52–1.7) | .79 | … | … |
| Antibiotic resistant | ||||
| Ceftriaxone | 2.1 (1.2–3.5) | .01 | … | … |
| Cefepime | 3.8 (1.9–7.7) | <.001 | … | … |
| Piperacillin-tazobactam | 2.9 (1.5–5.5) | .00 | … | … |
| Aminoglycoside | 1.9 (.93–3.9) | .08 | … | … |
| Fluoroquinolone | 1.4 (.76–2.4) | .29 | … | … |
| MDR | 1.7 (.94–3.1) | .08 | … | … |
| Delay of ≥4 h to antibiotic treatment | 1.5 (.9–2.4) | .12 | … | … |
| Incorrect 1st antibiotic | 3.8 (1.9–7.7) | <.001 | 5.22 (2.21–12.37) | <.001 |
| ID consultation | 0.83 (.51–1.3) | .44 | … | … |
| Hospital-acquired infection | 2.8 (1.7–4.5) | <.001 | … | … |
| ICU admission | 4.72 (2.86–7.79) | <.001 | 5.06 (2.82–9.07) | <.001 |
Abbreviations: ANC, absolute neutrophil count; CI, confidence interval; ICU, intensive care unit; ID, infectious diseases; MDR, multidrug resistance; OR, odds ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
